Aeglea BioTherapeutics
Biotechnology ResearchView the employees at
Aeglea BioTherapeutics-
Alex Delp Director of Product Operations at Aeglea BioTherapeutics
-
Austin, Texas, United States
-
Rising Star
Akeem Mustapha Associate Director, Clinical Data Management at Aeglea BioTherapeutics-
Dallas-Fort Worth Metroplex
-
Top 10%
Jonathan Campbell, CPA, CFE Corporate Controller at Aeglea BioTherapeutics (NASDAQ: AGLE)-
Austin, Texas, United States
-
Top 10%
Kristeon Strong Senior Manager of Quality Control at Aeglea BioTherapeutics-
Top 10%
Travis McCaddon Procurement Specialist at Aeglea BioTherapeutics-
Austin, Texas, United States
-
Rising Star
Overview
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. For more information, please visit http://aeglea.com.
-